<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2015-12-03" updated="2019-12-02">
  <drugbank-id primary="true">DB11131</drugbank-id>
  <name>Capsicum oleoresin</name>
  <description>Capsicum oleoresin is an oily organic resin derived from the fruit of plants in the Capsicum genus, such as chilli peppers. When the plants are finely ground, capsicum oleoresin is formed after the extraction process of capsaicin using oragnic solvents such as ethanol. It is commonly used as a culinary spice. The intensity of biological actions and toxicological effects of capsicum oleoresin are a direct function of the amount of capsaicinoids, or capsaicin, present in the compound [L1944]. Capsaicinoids comprise of a group of fat-soluble pungent chemical phenols and include [DB06774], dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin, and homodihydrocapsaicin [A32318]. [DB06774] and dihydrocapsaicin are the most pungent capsaicinoid analogues [A32318].&#13;
&#13;
Capsicum oleoresin is contained in pepper sprays when suspended in water, and acts an active lachrymatory agent that induces irritation, lacrimation, pain, and temporary blindness when in contact with eyes. Due to its analgesic properties, capsicum oleoresin is used to temporarily relieve of minor aches and pains of muscles and joints as an active ingredient in topical OTC preparations and has been studied for management of different models of neuropathic pain [A32316]. It is suggested that capsicum oleoresin is a rich source of phytochemicals that consist of phenolic compounds with antioxidant and antidiabetic activities [A32317].</description>
  <cas-number>8023-77-6</cas-number>
  <unii>UW86K581WY</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A32316</ref-id>
        <pubmed-id>22849599</pubmed-id>
        <citation>Groninger H, Schisler RE: Topical capsaicin for neuropathic pain #255. J Palliat Med. 2012 Aug;15(8):946-7. doi: 10.1089/jpm.2012.9571.</citation>
      </article>
      <article>
        <ref-id>A32317</ref-id>
        <pubmed-id>27544798</pubmed-id>
        <citation>Sricharoen P, Lamaiphan N, Patthawaro P, Limchoowong N, Techawongstien S, Chanthai S: Phytochemicals in Capsicum oleoresin from different varieties of hot chilli peppers with their antidiabetic and antioxidant activities due to some phenolic compounds. Ultrason Sonochem. 2017 Sep;38:629-639. doi: 10.1016/j.ultsonch.2016.08.018. Epub 2016 Aug 12.</citation>
      </article>
      <article>
        <ref-id>A32318</ref-id>
        <pubmed-id>26554271</pubmed-id>
        <citation>Yeung MF, Tang WY: Clinicopathological effects of pepper (oleoresin capsicum) spray. Hong Kong Med J. 2015 Dec;21(6):542-52. doi: 10.12809/hkmj154691. Epub 2015 Nov 6.</citation>
      </article>
      <article>
        <ref-id>A32319</ref-id>
        <pubmed-id>23023032</pubmed-id>
        <citation>O'Neill J, Brock C, Olesen AE, Andresen T, Nilsson M, Dickenson AH: Unravelling the mystery of capsaicin: a tool to understand and treat pain. Pharmacol Rev. 2012 Oct;64(4):939-71. doi: 10.1124/pr.112.006163.</citation>
      </article>
      <article>
        <ref-id>A32323</ref-id>
        <pubmed-id>27367653</pubmed-id>
        <citation>Fattori V, Hohmann MS, Rossaneis AC, Pinho-Ribeiro FA, Verri WA: Capsaicin: Current Understanding of Its Mechanisms and Therapy of Pain and Other Pre-Clinical and Clinical Uses. Molecules. 2016 Jun 28;21(7). pii: molecules21070844. doi: 10.3390/molecules21070844.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L1944</ref-id>
        <title>Oleoresin Capsicum Toxicology Evaluation and Hazard Review</title>
        <url>http://prod.sandia.gov/techlib/access-control.cgi/1995/952129.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Indicated for the temporary relief of minor aches and pains of muscles and joints associated with simple backache, arthritis, strains and sprains. </indication>
  <pharmacodynamics>Capsicum oleoresin is a topical analgesic and inflammatory agent. Capsaicin, an active ingredient in capsicum oleoresin, causes pain and sensitization of both peripheral and central nerves. It induces primary and secondary hyperalgesia and mimics the symptoms associated with neuropathic pain, such as allodynia, secondary hyperalgesia, referred pain area, and viscerovisceral hyperalgesia [A32319]. In opposition, capsaicin also mediates analgesic actions via desensitization and withdrawal of epidermal nerve fibers [A32319]. Systemic reviews of capsaicin-containing topical formulations demonstrate clinical effectiveness for pain reduction in postherpetic neuralgia, postsurgical neuropathies, and diabetic neuropathy, compared to placebo [A32316].</pharmacodynamics>
  <mechanism-of-action>Capsaicin is the active ingredient in capsicum oleoresin that confers the molecule its biological actions. It induces central sensitization to cause pain and depolarizes nociceptors to increases their cytosolic free Ca2+ concentration [A32319]. It is a highly selective agonist and activator at the transient receptor potential vanilloid subfamily member 1 (TRPV1) receptors expressed in afferent neuronal C fibers and some Aδ fibers [A32316]. The aliphatic tail of capsaicin interacts with the channel via nonspecific Van der Waals forces, while hydrogen bonds between its vanillyl “head” and amide “neck” with residues of glutamic acid E571 and T551 of the channel, respectively, confers specificity for ligand binding [A32323]. Binding and local activation of these receptors lead to increased influx of calcium ions and nerve depolarization. Signal propagation to the central nervous system causes local heat, stinging, and/or itching sensations [A32316]. Prolonged activation of TRPV1 receptors results in loss of receptor functionality, causing impaired local nociception for extended periods due to desensitization and inactivation of sensory neurons. It is thought that the activation of TRPV1 receptors is the main mechanism of action of capsaicin. Capsaicin also induces a local depletion of substance P, which is a neuropeptide involved in visceral pain signalling [A32323]; however this effect in the relief of pain remains controversial [A32316]. </mechanism-of-action>
  <toxicity>Acute oral LD50, acute dermal LD50 and acute inhalation LD50 in rat are &gt;3000mg/kg, &gt;2500 mg/kg, and &gt;10000 mg/m^3, respectively [MSDS]. Capsicum oleoresin is not considered to be a carcinogen. There has been no case reports or findings from studies indicating teratogenic potential of capsaicinoid [L1944]. &#13;
&#13;
Capsicum oleoresin can cause serious irritation, conjunctivitis and lacrimation via contact with eyes. It induces a burning sensation and pain in case of contact with eyes and skin. As it is also irritating to the respiratory system, it causes lung irritation and coughing as well as bronchoconstriction. Other respiratory effects include laryngospasm, swelling of the larynx and lungs, chemical pneumonitis,respiratory arrest and central nervous system effects such as convulsions and excitement. In case of ingestion, gastrointestinal tract irritation may be observed along with a sensation of warmth or painful burning [MSDS]. Symptoms of systemic toxicity include disorientation, fear, loss of body motor control including diminished hand-eye coordination, hyperventilation, tachycardia, and pulmonary oedema [L1944]. Careful early decontamination is recommended and medical intervention should be initiated for any life-threatening symptoms. In case of contact, individual must be removed from the source of exposure and the contacted skin and mucous membranes should be thoroughly washed with copious amounts of water [L1944].</toxicity>
  <metabolism>For pharmacokinetic properties of capsaicin, refer to the drug entry for [DB06774].</metabolism>
  <absorption>For pharmacokinetic properties of capsaicin, refer to the drug entry for [DB06774].</absorption>
  <half-life>For pharmacokinetic properties of capsaicin, refer to the drug entry for [DB06774].</half-life>
  <protein-binding>For pharmacokinetic properties of capsaicin, refer to the drug entry for [DB06774].</protein-binding>
  <route-of-elimination>For pharmacokinetic properties of capsaicin, refer to the drug entry for [DB06774].</route-of-elimination>
  <volume-of-distribution>For pharmacokinetic properties of capsaicin, refer to the drug entry for [DB06774].</volume-of-distribution>
  <clearance>For pharmacokinetic properties of capsaicin, refer to the drug entry for [DB06774].</clearance>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Capsaicin oleoresin</synonym>
    <synonym language="english" coder="">Capsicum annuum resin</synonym>
    <synonym language="english" coder="">Capsicum capsicum resin</synonym>
    <synonym language="english" coder="">Capsicum longum resin</synonym>
    <synonym language="english" coder="">Cayenne pepper resin</synonym>
    <synonym language="english" coder="">Chili oleoresin</synonym>
    <synonym language="english" coder="">Oleoresin capsicum</synonym>
    <synonym language="english" coder="">Oleoresins of capsicum</synonym>
  </synonyms>
  <products>
    <product>
      <name>Arthricare for Women Ultra Strength</name>
      <labeller>Del Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230569</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-10-21</started-marketing-on>
      <ended-marketing-on>2003-07-21</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Biobalsam</name>
      <labeller>Biopharmatech Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02230695</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1997-06-11</started-marketing-on>
      <ended-marketing-on>1999-07-07</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Chakra Aroma Relaxing Color</name>
      <labeller>mooni studio</labeller>
      <ndc-id/>
      <ndc-product-code>72880-0100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength>0.2 g/1</strength>
      <route>Topical</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>DeramsilkRx Anodynexa Pak</name>
      <labeller>Patchwerx Labs</labeller>
      <ndc-id/>
      <ndc-product-code>69329-310</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA074514</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>DermacinRx Inflammatral Pak</name>
      <labeller>Pure Tek Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>59088-062</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA077863</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>DermacinRx Lexitral PharmaPak</name>
      <labeller>PureTek Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>59088-343</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA202769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>DermacinRx Penetral Cream</name>
      <labeller>PureTek Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>59088-310</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>0.25 mg/1mL</strength>
      <route>Topical</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>DermasilkRx DicloPak</name>
      <labeller>Patchwerx Labs</labeller>
      <ndc-id/>
      <ndc-product-code>69329-330</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA074514</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>DermasilkRx DicloPak</name>
      <labeller>Patchwerx Labs</labeller>
      <ndc-id/>
      <ndc-product-code>69329-335</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA074514</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Diabet Aid</name>
      <labeller>Insight Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>63736-404</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Lotion</dosage-form>
      <strength>0.25 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Diclotral Pak</name>
      <labeller>Patchwerx Labs</labeller>
      <ndc-id/>
      <ndc-product-code>69329-510</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA202027</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Essentials Herbal Muscle Massage</name>
      <labeller>Arbonne International, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>42508-282</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Family Care Back Pain Therapy</name>
      <labeller>United Exchange Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>65923-901</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Fast Arthritis Aid</name>
      <labeller>Concept Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>64058-213</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Gel</dosage-form>
      <strength>0.061 g/244g</strength>
      <route>Topical</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Flanax</name>
      <labeller>Belmora LLC</labeller>
      <ndc-id/>
      <ndc-product-code>27854-100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-06</started-marketing-on>
      <ended-marketing-on>2018-10-01</ended-marketing-on>
      <dosage-form>Liniment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Half and Half Balm</name>
      <labeller>Mueller Sports Medicine, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00240494</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1970-12-31</started-marketing-on>
      <ended-marketing-on>2003-08-01</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Herbalax Forte No 70 Tab</name>
      <labeller>SantÉ Naturelle (Ag) LtÉe</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00511390</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1981-12-31</started-marketing-on>
      <ended-marketing-on>1997-09-09</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Hot Stuff</name>
      <labeller>Mueller Sports Medicine, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>52564-308</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>0.0265 g/106g</strength>
      <route>Topical</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Inflammacin</name>
      <labeller>PureTek Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>59088-093</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-01-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA075185</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Medicated Pain Relief Hot</name>
      <labeller>Kareway Product, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>67510-0026</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-09-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Patch</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Mobility</name>
      <labeller>Mayway Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>33346-3401</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Oil</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Oriental Magic Oil</name>
      <labeller>Wei Yuan Trading Inc</labeller>
      <ndc-id/>
      <ndc-product-code>71757-100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Oil</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PrevidolRx Analgesic Pak</name>
      <labeller>GenPak Solutions, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>75840-094</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA077863</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PrevidolRx Plus Analgesic Pak</name>
      <labeller>GenPak Solutions, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>75840-095</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA077863</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Relief Recovery</name>
      <labeller>Mayway Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>33346-3400</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Oil</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sheffield Arthritis and Muscle Pain Relief</name>
      <labeller>Sheffield Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>11527-089</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-04-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>0.25 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Super Arthritis Pain Relief</name>
      <labeller>Herbalife International of America, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02238080</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-11-01</started-marketing-on>
      <ended-marketing-on>2002-09-17</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Takahi Hot Medicated Plaster</name>
      <labeller>Indo Abadi Sari Makmur, Pt</labeller>
      <ndc-id/>
      <ndc-product-code>70815-003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Plaster</dosage-form>
      <strength/>
      <route>Transdermal</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Thermacare Ultra</name>
      <labeller>Wyeth Consumer Healthcare Llc</labeller>
      <ndc-id/>
      <ndc-product-code>0573-3023</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Trixaicin</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0566</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-01</started-marketing-on>
      <ended-marketing-on>2018-02-28</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength>0.25 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Trixaicin</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-0648</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-01</started-marketing-on>
      <ended-marketing-on>2018-02-28</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength>0.25 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Trixaicin HP</name>
      <labeller>Qualitest</labeller>
      <ndc-id/>
      <ndc-product-code>0603-0649</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-01</started-marketing-on>
      <ended-marketing-on>2015-11-26</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength>0.75 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>part348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Watkins Analgesic Balm</name>
      <labeller>Watkins Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00376450</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1977-12-31</started-marketing-on>
      <ended-marketing-on>1997-08-25</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Xelitral</name>
      <labeller>Shoreline Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69621-343</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA202769</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Xenaflamm</name>
      <labeller>Shoreline Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>69621-093</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number>ANDA075185</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Medicated Pain Relief Hot</name>
      <ingredients>Capsicum oleoresin + Levomenthol</ingredients>
    </mixture>
    <mixture>
      <name>Family Care Back Pain Therapy</name>
      <ingredients>Capsicum oleoresin + Levomenthol + Synthetic camphor</ingredients>
    </mixture>
    <mixture>
      <name>DermacinRx Inflammatral Pak</name>
      <ingredients>Capsicum oleoresin + Diclofenac + Ranitidine</ingredients>
    </mixture>
    <mixture>
      <name>DeramsilkRx Anodynexa Pak</name>
      <ingredients>Capsicum oleoresin + Diclofenac + Ranitidine</ingredients>
    </mixture>
    <mixture>
      <name>DermasilkRx DicloPak</name>
      <ingredients>Capsicum oleoresin + Diclofenac</ingredients>
    </mixture>
    <mixture>
      <name>DermasilkRx DicloPak</name>
      <ingredients>Capsicum oleoresin + Diclofenac</ingredients>
    </mixture>
    <mixture>
      <name>Fast Arthritis Aid</name>
      <ingredients>Capsicum oleoresin</ingredients>
    </mixture>
    <mixture>
      <name>Trixaicin</name>
      <ingredients>Capsicum oleoresin</ingredients>
    </mixture>
    <mixture>
      <name>Flanax</name>
      <ingredients>Capsicum oleoresin + Levomenthol + Methyl salicylate</ingredients>
    </mixture>
    <mixture>
      <name>Xelitral</name>
      <ingredients>Capsicum oleoresin + Diclofenac</ingredients>
    </mixture>
    <mixture>
      <name>Trixaicin HP</name>
      <ingredients>Capsicum oleoresin</ingredients>
    </mixture>
    <mixture>
      <name>Xenaflamm</name>
      <ingredients>Capsicum oleoresin + Diclofenac</ingredients>
    </mixture>
    <mixture>
      <name>Hot Stuff</name>
      <ingredients>Capsicum oleoresin</ingredients>
    </mixture>
    <mixture>
      <name>PrevidolRx Plus Analgesic Pak</name>
      <ingredients>Capsicum oleoresin + Diclofenac</ingredients>
    </mixture>
    <mixture>
      <name>PrevidolRx Analgesic Pak</name>
      <ingredients>Capsicum oleoresin + Diclofenac + Omeprazole</ingredients>
    </mixture>
    <mixture>
      <name>Diclotral Pak</name>
      <ingredients>Capsicum oleoresin + Diclofenac</ingredients>
    </mixture>
    <mixture>
      <name>Trixaicin</name>
      <ingredients>Capsicum oleoresin</ingredients>
    </mixture>
    <mixture>
      <name>Takahi Hot Medicated Plaster</name>
      <ingredients>Capsicum oleoresin + Synthetic camphor</ingredients>
    </mixture>
    <mixture>
      <name>Oriental Magic Oil</name>
      <ingredients>Camphor + Capsicum oleoresin + Levomenthol + Methyl salicylate</ingredients>
    </mixture>
    <mixture>
      <name>Thermacare Ultra</name>
      <ingredients>Capsicum oleoresin + Levomenthol + Methyl salicylate + Synthetic camphor</ingredients>
    </mixture>
    <mixture>
      <name>Essentials Herbal Muscle Massage</name>
      <ingredients>Capsicum oleoresin + Methyl salicylate + Racementhol</ingredients>
    </mixture>
    <mixture>
      <name>DermacinRx Penetral Cream</name>
      <ingredients>Capsicum oleoresin</ingredients>
    </mixture>
    <mixture>
      <name>Chakra Aroma Relaxing Color</name>
      <ingredients>Capsicum oleoresin</ingredients>
    </mixture>
    <mixture>
      <name>DermacinRx Lexitral PharmaPak</name>
      <ingredients>Capsicum oleoresin + Diclofenac</ingredients>
    </mixture>
    <mixture>
      <name>Inflammacin</name>
      <ingredients>Capsicum oleoresin + Diclofenac</ingredients>
    </mixture>
    <mixture>
      <name>Diabet Aid</name>
      <ingredients>Capsicum oleoresin</ingredients>
    </mixture>
    <mixture>
      <name>Mobility</name>
      <ingredients>Camphor + Capsicum oleoresin + Levomenthol + Methyl salicylate</ingredients>
    </mixture>
    <mixture>
      <name>Relief Recovery</name>
      <ingredients>Camphor + Capsicum oleoresin + Levomenthol + Methyl salicylate</ingredients>
    </mixture>
    <mixture>
      <name>Sheffield Arthritis and Muscle Pain Relief</name>
      <ingredients>Capsicum oleoresin</ingredients>
    </mixture>
    <mixture>
      <name>Half and Half Balm</name>
      <ingredients>Capsicum oleoresin + Levomenthol + Methyl salicylate + Turpentine</ingredients>
    </mixture>
    <mixture>
      <name>Watkins Analgesic Balm</name>
      <ingredients>Capsicum oleoresin + Levomenthol + Methyl salicylate + Turpentine</ingredients>
    </mixture>
    <mixture>
      <name>Herbalax Forte No 70 Tab</name>
      <ingredients>Capsicum oleoresin + Frangula purshiana bark + Papain + Phenolphthalein + Taurocholic acid</ingredients>
    </mixture>
    <mixture>
      <name>Arthricare for Women Ultra Strength</name>
      <ingredients>Capsicum oleoresin + Levomenthol</ingredients>
    </mixture>
    <mixture>
      <name>Biobalsam</name>
      <ingredients>Capsicum oleoresin + Methyl nicotinate</ingredients>
    </mixture>
    <mixture>
      <name>Super Arthritis Pain Relief</name>
      <ingredients>Capsicum oleoresin</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Biological Products</category>
      <mesh-id>D001688</mesh-id>
    </category>
    <category>
      <category>Complex Mixtures</category>
      <mesh-id>D045424</mesh-id>
    </category>
    <category>
      <category>Pharmaceutical Preparations</category>
      <mesh-id>D004364</mesh-id>
    </category>
    <category>
      <category>Plant Preparations</category>
      <mesh-id>D028321</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Patch</form>
      <route>Topical</route>
      <strength>0.2 g/1</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>0.25 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Lotion</form>
      <route>Topical</route>
      <strength>0.25 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Gel</form>
      <route>Topical</route>
      <strength>0.061 g/244g</strength>
    </dosage>
    <dosage>
      <form>Liniment</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Ointment</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>0.0265 g/106g</strength>
    </dosage>
    <dosage>
      <form>Patch</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Oil</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Plaster</form>
      <route>Transdermal</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>0.25 mg/1g</strength>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>0.75 mg/1g</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB11131.pdf?1522339138</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Fully dispersible</value>
      <source>"Oleoresin Capsicum Toxicology Evaluation and Hazard Review.", National Institute of Justice Less-Than-Lethal Force Program, 1995</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>&lt;60</value>
      <source>"Oleoresin Capsicum Toxicology Evaluation and Hazard Review.", National Institute of Justice Less-Than-Lethal Force Program, 1995</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>&gt;187</value>
      <source>"Oleoresin Capsicum Toxicology Evaluation and Hazard Review.", National Institute of Justice Less-Than-Lethal Force Program, 1995</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C18H27NO3</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>3610</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>3611</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347911130</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Pepper_spray</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0001023</id>
      <name>Transient receptor potential cation channel subfamily V member 1</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
        <action>activator</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A32316</ref-id>
            <pubmed-id>22849599</pubmed-id>
            <citation>Groninger H, Schisler RE: Topical capsaicin for neuropathic pain #255. J Palliat Med. 2012 Aug;15(8):946-7. doi: 10.1089/jpm.2012.9571.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q8NER1" source="Swiss-Prot">
        <name>Transient receptor potential cation channel subfamily V member 1</name>
        <general-function>Transmembrane signaling receptor activity</general-function>
        <specific-function>Ligand-activated non-selective calcium permeant cation channel involved in detection of noxious chemical and thermal stimuli. Seems to mediate proton influx and may be involved in intracellular acidosis in nociceptive neurons. Involved in mediation of inflammatory pain and hyperalgesia. Sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. Can be activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin. Acts as ionotropic endocannabinoid receptor with central neuromodulatory effects. Triggers a form of long-term depression (TRPV1-LTD) mediated by the endocannabinoid anandamine in the hippocampus and nucleus accumbens by affecting AMPA receptors endocytosis (By similarity). Activation by vanilloids, like capsaicin, and temperatures higher than 42 degrees Celsius, exhibits a time- and Ca(2+)-dependent outward rectification, followed by a long-lasting refractory state. Mild extracellular acidic pH (6.5) potentiates channel activation by noxious heat and vanilloids, whereas acidic conditions (pH &lt;6) directly activate the channel.</specific-function>
        <gene-name>TRPV1</gene-name>
        <locus>17p13.3</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>434-454
472-497
511-531
536-556
572-599
659-687</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>7.26</theoretical-pi>
        <molecular-weight>94955.33</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:12716</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>TRPV1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AJ277028</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>8977866</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>507</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>507</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q8NER1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>TRPV1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Capsaicin receptor</synonym>
          <synonym>Osm-9-like TRP channel 1</synonym>
          <synonym>OTRPC1</synonym>
          <synonym>TrpV1</synonym>
          <synonym>Vanilloid receptor 1</synonym>
          <synonym>VR1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037113|Transient receptor potential cation channel subfamily V member 1
MKKWSSTDLGAAADPLQKDTCPDPLDGDPNSRPPPAKPQLSTAKSRTRLFGKGDSEEAFP
VDCPHEEGELDSCPTITVSPVITIQRPGDGPTGARLLSQDSVAASTEKTLRLYDRRSIFE
AVAQNNCQDLESLLLFLQKSKKHLTDNEFKDPETGKTCLLKAMLNLHDGQNTTIPLLLEI
ARQTDSLKELVNASYTDSYYKGQTALHIAIERRNMALVTLLVENGADVQAAAHGDFFKKT
KGRPGFYFGELPLSLAACTNQLGIVKFLLQNSWQTADISARDSVGNTVLHALVEVADNTA
DNTKFVTSMYNEILMLGAKLHPTLKLEELTNKKGMTPLALAAGTGKIGVLAYILQREIQE
PECRHLSRKFTEWAYGPVHSSLYDLSCIDTCEKNSVLEVIAYSSSETPNRHDMLLVEPLN
RLLQDKWDRFVKRIFYFNFLVYCLYMIIFTMAAYYRPVDGLPPFKMEKTGDYFRVTGEIL
SVLGGVYFFFRGIQYFLQRRPSMKTLFVDSYSEMLFFLQSLFMLATVVLYFSHLKEYVAS
MVFSLALGWTNMLYYTRGFQQMGIYAVMIEKMILRDLCRFMFVYIVFLFGFSTAVVTLIE
DGKNDSLPSESTSHRWRGPACRPPDSSYNSLYSTCLELFKFTIGMGDLEFTENYDFKAVF
IILLLAYVILTYILLLNMLIALMGETVNKIAQESKNIWKLQRAITILDTEKSFLKCMRKA
FRSGKLLQVGYTPDGKDDYRWCFRVDEVNWTTWNTNVGIINEDPGNCEGVKRTLSFSLRS
SRVSGRHWKNFALVPLLREASARDRQSAQPEEVYLRQFSGSLKPEDAEVFKSPAASGEK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020500|Transient receptor potential cation channel subfamily V member 1 (TRPV1)
ATGAAGAAATGGAGCAGCACAGACTTGGGGGCAGCTGCGGACCCACTCCAAAAGGACACC
TGCCCAGACCCCCTGGATGGAGACCCTAACTCCAGGCCACCTCCAGCCAAGCCCCAGCTC
TCCACGGCCAAGAGCCGCACCCGGCTCTTTGGGAAGGGTGACTCGGAGGAGGCTTTCCCG
GTGGATTGCCCTCACGAGGAAGGTGAGCTGGACTCCTGCCCGACCATCACAGTCAGCCCT
GTTATCACCATCCAGAGGCCAGGAGACGGCCCCACCGGTGCCAGGCTGCTGTCCCAGGAC
TCTGTCGCCGCCAGCACCGAGAAGACCCTCAGGCTCTATGATCGCAGGAGTATCTTTGAA
GCCGTTGCTCAGAATAACTGCCAGGATCTGGAGAGCCTGCTGCTCTTCCTGCAGAAGAGC
AAGAAGCACCTCACAGACAACGAGTTCAAAGACCCTGAGACAGGGAAGACCTGTCTGCTG
AAAGCCATGCTCAACCTGCACGACGGACAGAACACCACCATCCCCCTGCTCCTGGAGATC
GCGCGGCAAACGGACAGCCTGAAGGAGCTTGTCAACGCCAGCTACACGGACAGCTACTAC
AAGGGCCAGACAGCACTGCACATCGCCATCGAGAGACGCAACATGGCCCTGGTGACCCTC
CTGGTGGAGAACGGAGCAGACGTCCAGGCTGCGGCCCATGGGGACTTCTTTAAGAAAACC
AAAGGGCGGCCTGGATTCTACTTCGGTGAACTGCCCCTGTCCCTGGCCGCGTGCACCAAC
CAGCTGGGCATCGTGAAGTTCCTGCTGCAGAACTCCTGGCAGACGGCCGACATCAGCGCC
AGGGACTCGGTGGGCAACACGGTGCTGCACGCCCTGGTGGAGGTGGCCGACAACACGGCC
GACAACACGAAGTTTGTGACGAGCATGTACAATGAGATTCTGATGCTGGGGGCCAAACTG
CACCCGACGCTGAAGCTGGAGGAGCTCACCAACAAGAAGGGAATGACGCCGCTGGCTCTG
GCAGCTGGGACCGGGAAGATCGGGGTCTTGGCCTATATTCTCCAGCGGGAGATCCAGGAG
CCCGAGTGCAGGCACCTGTCCAGGAAGTTCACCGAGTGGGCCTACGGGCCCGTGCACTCC
TCGCTGTACGACCTGTCCTGCATCGACACCTGCGAGAAGAACTCGGTGCTGGAGGTGATC
GCCTACAGCAGCAGCGAGACCCCTAATCGCCACGACATGCTCTTGGTGGAGCCGCTGAAC
CGACTCCTGCAGGACAAGTGGGACAGATTCGTCAAGCGCATCTTCTACTTCAACTTCCTG
GTCTACTGCCTGTACATGATCATCTTCACCATGGCTGCCTACTACAGGCCCGTGGATGGC
TTGCCTCCCTTTAAGATGGAAAAAACTGGAGACTATTTCCGAGTTACTGGAGAGATCCTG
TCTGTGTTAGGAGGAGTCTACTTCTTTTTCCGAGGGATTCAGTATTTCCTGCAGAGGCGG
CCGTCGATGAAGACCCTGTTTGTGGACAGCTACAGTGAGATGCTTTTCTTTCTGCAGTCA
CTGTTCATGCTGGCCACCGTGGTGCTGTACTTCAGCCACCTCAAGGAGTATGTGGCTTCC
ATGGTATTCTCCCTGGCCTTGGGCTGGACCAACATGCTCTACTACACCCGCGGTTTCCAG
CAGATGGGCATCTATGCCGTCATGATAGAGAAGATGATCCTGAGAGACCTGTGCCGTTTC
ATGTTTGTCTACATCGTCTTCTTGTTCGGGTTTTCCACAGCGGTGGTGACGCTGATTGAA
GACGGGAAGAATGACTCCCTGCCGTCTGAGTCCACGTCGCACAGGTGGCGGGGGCCTGCC
TGCAGGCCCCCCGATAGCTCCTACAACAGCCTGTACTCCACCTGCCTGGAGCTGTTCAAG
TTCACCATCGGCATGGGCGACCTGGAGTTCACTGAGAACTATGACTTCAAGGCTGTCTTC
ATCATCCTGCTGCTGGCCTATGTAATTCTCACCTACATCCTCCTGCTCAACATGCTCATC
GCCCTCATGGGTGAGACTGTCAACAAGATCGCACAGGAGAGCAAGAACATCTGGAAGCTG
CAGAGAGCCATCACCATCCTGGACACGGAGAAGAGCTTCCTTAAGTGCATGAGGAAGGCC
TTCCGCTCAGGCAAGCTGCTGCAGGTGGGGTACACACCTGATGGCAAGGACGACTACCGG
TGGTGCTTCAGGGTGGACGAGGTGAACTGGACCACCTGGAACACCAACGTGGGCATCATC
AACGAAGACCCGGGCAACTGTGAGGGCGTCAAGCGCACCCTGAGCTTCTCCCTGCGGTCA
AGCAGAGTTTCAGGCAGACACTGGAAGAACTTTGCCCTGGTCCCCCTTTTAAGAGAGGCA
AGTGCTCGAGATAGGCAGTCTGCTCAGCCCGAGGAAGTTTATCTGCGACAGTTTTCAGGG
TCTCTGAAGCCAGAGGACGCTGAGGTCTTCAAGAGTCCTGCCGCTTCCGGGGAGAAGTGA
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00520</identifier>
            <name>Ion_trans</name>
          </pfam>
          <pfam>
            <identifier>PF12796</identifier>
            <name>Ank_2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic spine membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intrinsic component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium-release channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>excitatory extracellular ligand-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphoprotein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transmembrane signaling receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell surface receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to alkaloid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to ATP</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chemosensory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thermoception</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>